Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received a consensus recommendation of “Hold” from the ten research firms that are covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $42.60.
Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $55.00 price target on shares of Theravance Biopharma in a research report on Tuesday, September 26th. Evercore ISI assumed coverage on shares of Theravance Biopharma in a research report on Wednesday, August 16th. They set an “outperform” rating and a $45.00 price target on the stock. Finally, BidaskClub lowered shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd.
COPYRIGHT VIOLATION NOTICE: This story was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.com-unik.info/2017/10/10/brokerages-set-theravance-biopharma-inc-tbph-target-price-at-42-60.html.
In other news, CEO Rick E. Winningham bought 10,000 shares of the business’s stock in a transaction on Friday, August 11th. The shares were bought at an average price of $24.50 per share, with a total value of $245,000.00. Following the completion of the transaction, the chief executive officer now directly owns 866,377 shares in the company, valued at $21,226,236.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Bradford J. Shafer sold 14,670 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total value of $451,395.90. Following the completion of the sale, the executive vice president now directly owns 134,327 shares in the company, valued at approximately $4,133,241.79. The disclosure for this sale can be found here. In the last three months, insiders acquired 20,000 shares of company stock worth $494,300. 6.10% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in TBPH. Wells Fargo & Company MN raised its position in Theravance Biopharma by 10.6% in the first quarter. Wells Fargo & Company MN now owns 32,270 shares of the biopharmaceutical company’s stock valued at $1,188,000 after purchasing an additional 3,100 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Theravance Biopharma by 2.6% in the first quarter. Bank of New York Mellon Corp now owns 206,023 shares of the biopharmaceutical company’s stock worth $7,586,000 after acquiring an additional 5,188 shares in the last quarter. Swiss National Bank grew its stake in shares of Theravance Biopharma by 1.7% in the first quarter. Swiss National Bank now owns 64,442 shares of the biopharmaceutical company’s stock worth $2,373,000 after acquiring an additional 1,100 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in shares of Theravance Biopharma by 3.3% in the first quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock worth $519,000 after acquiring an additional 456 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 3,407 shares in the last quarter. 84.84% of the stock is currently owned by institutional investors.
Theravance Biopharma (NASDAQ TBPH) traded down 5.11% on Friday, hitting $32.70. The stock had a trading volume of 178,505 shares. The stock’s market cap is $1.76 billion. Theravance Biopharma has a 12 month low of $23.15 and a 12 month high of $43.44. The firm’s 50 day moving average price is $32.11 and its 200-day moving average price is $35.56.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
What are top analysts saying about Theravance Biopharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Theravance Biopharma Inc. and related companies.